2021 Q4 Form 10-Q Financial Statement

#000095017021004376 Filed on November 12, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2021 Q1

Balance Sheet

Concept 2021 Q4 2021 Q3 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $464.2M $512.7M $550.7M
YoY Change -26.67% 39.77% 286.73%
Cash & Equivalents $77.42M $87.25M $97.83M
Short-Term Investments $386.8M $425.4M $452.9M
Other Short-Term Assets $9.108M $7.672M $8.100M
YoY Change 586.36% 16.24% 145.45%
Inventory
Prepaid Expenses $6.065M
Receivables
Other Receivables
Total Short-Term Assets $486.4M $534.9M $573.9M
YoY Change -25.68% 28.68% 224.97%
LONG-TERM ASSETS
Property, Plant & Equipment $13.93M $14.74M $1.420M
YoY Change 816.25% 781.64% -35.45%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $26.05M $19.09M $53.00M
YoY Change 108.38% 8.45%
Other Assets $12.61M $12.94M $15.00M
YoY Change 1.14% 3.78% 11.11%
Total Long-Term Assets $74.66M $67.34M $76.30M
YoY Change 181.48% 112.19% 382.91%
TOTAL ASSETS
Total Short-Term Assets $486.4M $534.9M $573.9M
Total Long-Term Assets $74.66M $67.34M $76.30M
Total Assets $561.1M $602.2M $650.2M
YoY Change -17.61% 34.61% 237.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.145M $4.595M $2.900M
YoY Change -3.49% 23.62% 45.0%
Accrued Expenses $25.75M $23.45M $26.71M
YoY Change -5.0% -11.49% 39.09%
Deferred Revenue $0.00
YoY Change -100.0%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $35.09M $32.63M $28.60M
YoY Change 10.69% 6.42% 30.59%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $27.62M $26.76M $5.200M
YoY Change 2661.7% 2332.73% 205.88%
Total Long-Term Liabilities $27.62M $26.76M $5.200M
YoY Change 2661.7% 2332.73% 205.88%
TOTAL LIABILITIES
Total Short-Term Liabilities $35.09M $32.63M $28.60M
Total Long-Term Liabilities $27.62M $26.76M $5.200M
Total Liabilities $62.71M $59.39M $33.80M
YoY Change 91.6% 86.81% 43.22%
SHAREHOLDERS EQUITY
Retained Earnings -$230.4M -$180.2M
YoY Change 301.28% 525.39%
Common Stock $728.7M $723.1M
YoY Change 3.27% 62.7%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $498.4M $542.8M $616.5M
YoY Change
Total Liabilities & Shareholders Equity $561.1M $602.2M $650.2M
YoY Change -17.61% 34.61% 237.94%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2021 Q1

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001538927
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2011-12-31
dei Amendment Flag
AmendmentFlag
false
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39333
dei Entity Registrant Name
EntityRegistrantName
Forma Therapeutics Holdings, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
37-1657129
dei Entity Address Address Line1
EntityAddressAddressLine1
300 North Beacon Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 501
dei Entity Address City Or Town
EntityAddressCityOrTown
Watertown
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02472
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
679-1970
dei Security12b Title
Security12bTitle
Common stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
FMTX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
47404601
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
87248000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
282689000
CY2021Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
425433000
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
350365000
CY2021Q3 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
14066000
CY2020Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
15273000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8139000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6120000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
534886000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
654447000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14741000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1520000
CY2021Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
19088000
CY2020Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
12534000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20569000
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
12941000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
12470000
CY2021Q3 us-gaap Assets
Assets
602225000
CY2020Q4 us-gaap Assets
Assets
680971000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4595000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4295000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
23453000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
27104000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4541000
CY2021Q3 us-gaap Taxes Payable Current
TaxesPayableCurrent
45000
CY2020Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
301000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
32634000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
31700000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
26760000
CY2020Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1027000
CY2021Q3 us-gaap Liabilities
Liabilities
59394000
CY2020Q4 us-gaap Liabilities
Liabilities
32727000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47399873
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47300231
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47378041
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47248685
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
47000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
47000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
723033000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
705607000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-180249000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-57410000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
542831000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
648244000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
602225000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
680971000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30684000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24780000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
88614000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
68501000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12749000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7460000
us-gaap Operating Expenses
OperatingExpenses
123701000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
35087000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22841000
us-gaap Restructuring Charges
RestructuringCharges
63000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
43433000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
32240000
us-gaap Operating Expenses
OperatingExpenses
91405000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-43433000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-32240000
us-gaap Operating Income Loss
OperatingIncomeLoss
-123701000
us-gaap Operating Income Loss
OperatingIncomeLoss
-91405000
fmtx Gain On Hit Discovery Divestiture
GainOnHitDiscoveryDivestiture
23312000
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
216000
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
870000
us-gaap Investment Income Interest
InvestmentIncomeInterest
770000
us-gaap Investment Income Interest
InvestmentIncomeInterest
2406000
CY2021Q3 us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
-70000
CY2020Q3 us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
-52000
us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
215000
us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
-2668000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
146000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
818000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
985000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
23050000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-43287000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-31422000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-122716000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-68355000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3806000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
123000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-26529000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-43294000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-27616000
us-gaap Net Income Loss
NetIncomeLoss
-122839000
us-gaap Net Income Loss
NetIncomeLoss
-41826000
fmtx Accretion Of Cumulative Dividends And Issuance Costs On Series Redeemable Convertible Preferred Stock Basic
AccretionOfCumulativeDividendsAndIssuanceCostsOnSeriesRedeemableConvertiblePreferredStockBasic
-3736000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-43294000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-27616000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-122839000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-45562000
CY2020Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-8000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-43294000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-27624000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-122839000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-45562000
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.91
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.67
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.60
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.74
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.91
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.67
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.60
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.74
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47365704
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41088261
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47333652
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16616143
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47365704
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-43585000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
579395000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16616143
CY2020Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
25587000
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41088924
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47333652
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
18246000
CY2020Q1 fmtx Accretion Of Cumulative Dividends On Redeemable Convertible Preferred Stock
AccretionOfCumulativeDividendsOnRedeemableConvertiblePreferredStock
-1936000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3000
CY2020Q1 fmtx Stock Issued During Period Value Exercise Of Warrants To Purchase Common Stock
StockIssuedDuringPeriodValueExerciseOfWarrantsToPurchaseCommonStock
12000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1210000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
11230000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
28765000
CY2020Q2 fmtx Accretion Of Cumulative Dividends On Redeemable Convertible Preferred Stock
AccretionOfCumulativeDividendsOnRedeemableConvertiblePreferredStock
-1800000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1256000
CY2020Q2 fmtx Conversion Of Temporary Equity To Common Stock Value
ConversionOfTemporaryEquityToCommonStockValue
141867000
CY2020Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
25587000
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
293707000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
142000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-25440000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
438497000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2129000
CY2020Q3 fmtx Change In Estimate Of Initial Public Offering Costs
ChangeInEstimateOfInitialPublicOfferingCosts
-369000
CY2020Q3 fmtx Stock Issued During Period Value Exercise Of Warrants To Purchase Common Stock
StockIssuedDuringPeriodValueExerciseOfWarrantsToPurchaseCommonStock
2961000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-27616000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
415602000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
648244000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
333000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3848000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-35960000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
616465000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
92000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6423000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
29000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6701000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-43294000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
542831000
us-gaap Profit Loss
ProfitLoss
-122839000
us-gaap Profit Loss
ProfitLoss
-41826000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
672000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1076000
fmtx Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
813000
fmtx Gain Loss On Lease Modification
GainLossOnLeaseModification
287000
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
16972000
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
4595000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
2597000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-1024000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-192000
fmtx Gain On Hit Discovery Divestiture
GainOnHitDiscoveryDivestiture
23312000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-121000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-89000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-227000
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-1207000
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
26555000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2348000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5432000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
272000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
355000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-3029000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
6280000
us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
-256000
us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
451000
fmtx Increase Decrease In Deferred Rent Noncurrent
IncreaseDecreaseInDeferredRentNoncurrent
-298000
fmtx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-907000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-108585000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-83099000
us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
514121000
us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
343320000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
431475000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
38647000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3721000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
134000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-86367000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-301967000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
293707000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
12000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
454000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
145000
fmtx Payment Of Public Offering Costs
PaymentOfPublicOfferingCosts
-943000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-489000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
293605000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-195441000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-91461000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
285159000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
173796000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
89718000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
82335000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
7478000
fmtx Operating Lease Right Of Use Asset Obtained
OperatingLeaseRightOfUseAssetObtained
19312000
fmtx Accretion Of Preferred Return And Cumulative Dividends On Preferred Securities
AccretionOfPreferredReturnAndCumulativeDividendsOnPreferredSecurities
3736000
fmtx Public Offering Costs Included In Accounts Payable And Accrued Expenses
PublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
28000
fmtx Public Offering Costs Included In Accounts Payable And Accrued Expenses
PublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
369000
fmtx Net Exercise Of Warrants To Purchase Common Stock
NetExerciseOfWarrantsToPurchaseCommonStock
2961000
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
277000
fmtx Installment Receivable In Prepaid Expenses And Other Current Assets
InstallmentReceivableInPrepaidExpensesAndOtherCurrentAssets
14131000
fmtx Equity Consideration In Other Assets
EquityConsiderationInOtherAssets
10000000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
3000
fmtx Conversion Of Redeemable Convertible And Convertible Preferred Stock In To Common Stocks
ConversionOfRedeemableConvertibleAndConvertiblePreferredStockInToCommonStocks
142252000
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q2 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
160000000
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
45.25
CY2020Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
795000
CY2020Q4 fmtx Gross Proceeds From Follow On Public Offering
GrossProceedsFromFollowOnPublicOffering
275800000
CY2020Q4 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
258600000
CY2021Q3 fmtx Aggregate Amount Of Issuance And Offering Cost
AggregateAmountOfIssuanceAndOfferingCost
200000000.0
CY2021Q3 fmtx Sales Agent Cash Commissions
SalesAgentCashCommissions
0.030
CY2021Q3 fmtx Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
531800000
fmtx Short Term Highly Liquid Investments With Original Maturities
ShortTermHighlyLiquidInvestmentsWithOriginalMaturities
90 days or less
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
87248000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
79865000
CY2021Q3 us-gaap Restricted Cash
RestrictedCash
2470000
CY2020Q3 us-gaap Restricted Cash
RestrictedCash
2470000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
89718000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
82335000
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
8900000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7500000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7478000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
27104000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
26705000
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3025000
CY2020Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1027000
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5879000
CY2021Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
529374000
CY2020Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
625392000
CY2020Q4 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
362912000
CY2021Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
92700000
CY2020Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
93700000
CY2020Q4 fmtx Manufacturing And Clinical Prepaid Expenses
ManufacturingAndClinicalPrepaidExpenses
3068000
CY2020Q3 fmtx Accretion Of Cumulative Dividends Redeemable Convertible Preferred Shares
AccretionOfCumulativeDividendsRedeemableConvertiblePreferredShares
46.37
CY2021Q3 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
444521000
CY2021Q3 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Gain
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
59000
CY2021Q3 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
20000
CY2021Q3 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
444560000
CY2020Q4 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
362899000
CY2020Q4 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Gain
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
38000
CY2020Q4 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
25000
CY2021Q3 fmtx Manufacturing And Clinical Prepaid Expenses
ManufacturingAndClinicalPrepaidExpenses
3187000
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
22427000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
13065000
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7686000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11545000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14741000
CY2021Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
4485000
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1725000
CY2021Q3 us-gaap Other Receivables
OtherReceivables
467000
CY2020Q4 us-gaap Other Receivables
OtherReceivables
1327000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8139000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6120000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1520000
CY2021Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
300000
CY2020Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
300000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
700000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1100000
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
312000
us-gaap Operating Lease Cost
OperatingLeaseCost
1112000
CY2021Q3 us-gaap Variable Lease Cost
VariableLeaseCost
255000
us-gaap Variable Lease Cost
VariableLeaseCost
738000
CY2021Q3 us-gaap Lease Cost
LeaseCost
567000
us-gaap Lease Cost
LeaseCost
1850000
CY2021Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
220000
us-gaap Operating Lease Payments
OperatingLeasePayments
1258000
CY2020Q4 fmtx Accrued Expenses And Other Liabilities Current Net
AccruedExpensesAndOtherLiabilitiesCurrentNet
27104000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6834000
CY2021Q3 fmtx Other Research And Development Related Accruals
OtherResearchAndDevelopmentRelatedAccruals
1567000
CY2020Q4 fmtx Other Research And Development Related Accruals
OtherResearchAndDevelopmentRelatedAccruals
338000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1110000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
4843000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
4986000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
4222000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
4349000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
27645000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
47155000
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
15854000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
31301000
fmtx Operating Lease Weighted Average Incremental Borrowing Rate Percent
OperatingLeaseWeightedAverageIncrementalBorrowingRatePercent
0.087
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y6M
CY2021Q3 fmtx Manufacturing And Clinical Accruals
ManufacturingAndClinicalAccruals
12922000
CY2020Q4 fmtx Manufacturing And Clinical Accruals
ManufacturingAndClinicalAccruals
17952000
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6898000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
967000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1008000
CY2021Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1099000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
972000
CY2021Q3 fmtx Accrued Expenses And Other Liabilities Current Net
AccruedExpensesAndOtherLiabilitiesCurrentNet
23453000
CY2021Q3 fmtx Cost For Guarantees And Indemnities
CostForGuaranteesAndIndemnities
0
CY2020Q4 fmtx Cost For Guarantees And Indemnities
CostForGuaranteesAndIndemnities
0
CY2019Q1 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.40
CY2019Q1 us-gaap Restructuring Charges
RestructuringCharges
5400000
us-gaap Restructuring And Related Activities Description
RestructuringAndRelatedActivitiesDescription
There were no restructuring activities during the nine months ended September 30, 2021
CY2019Q4 us-gaap Restructuring Reserve
RestructuringReserve
325000
us-gaap Restructuring Charges
RestructuringCharges
63000
us-gaap Severance Costs1
SeveranceCosts1
-388000
CY2020Q2 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
20349223
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10183274
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6701000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2129000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16972000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4595000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6701000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2129000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16972000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4595000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4941537
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.62
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y1M6D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
130802000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1363220
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
34.92
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
91560
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.14
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
51931
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
8.73
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6161266
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.49
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y6M
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
72281000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2173996
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.08
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y1M6D
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
33742000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0098
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0036
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
6161266
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
14.49
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
72281000
fmtx Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price1
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice1
34.92
fmtx Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price1
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice1
10.13
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0096
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0109
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.775
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.761
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.779
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.748
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2021Q3 fmtx Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price1
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice1
23.38
CY2020Q3 fmtx Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price1
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice1
40.82
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41088261
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41088924
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
100000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-26500000
us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
29600000
us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
16600000
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1239000
fmtx Contract With Customer Liability Current Deductions
ContractWithCustomerLiabilityCurrentDeductions
-1239000
us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
0
us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
0
CY2021Q3 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
CY2020Q3 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
us-gaap Proceeds From Divestiture Of Businesses Net Of Cash Divested
ProceedsFromDivestitureOfBusinessesNetOfCashDivested
17500000
CY2021Q3 fmtx Prepaid Of Reimbursement Expense
PrepaidOfReimbursementExpense
500000
CY2021Q3 fmtx Equity Consideration
EquityConsideration
10000000.0
CY2021Q3 fmtx Cash Due At Closing
CashDueAtClosing
2961000
CY2021Q3 fmtx Installment Receivable
InstallmentReceivable
12593000
CY2021Q3 fmtx Equity Consideration
EquityConsideration
10000000
CY2021Q3 fmtx Fair Value Of Consideration
FairValueOfConsideration
25554000
CY2021Q3 us-gaap Disposal Group Including Discontinued Operation Accounts Payable
DisposalGroupIncludingDiscontinuedOperationAccountsPayable
159000
CY2021Q3 us-gaap Disposal Group Including Discontinued Operation Deferred Revenue
DisposalGroupIncludingDiscontinuedOperationDeferredRevenue
1239000
CY2021Q3 us-gaap Liabilities Of Disposal Group Including Discontinued Operation
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
1398000
CY2021Q3 us-gaap Disposal Group Deferred Gain On Disposal
DisposalGroupDeferredGainOnDisposal
2242000
fmtx Impairment To Equity Consideration
ImpairmentToEquityConsideration
0
CY2020 fmtx Impairment To Equity Consideration
ImpairmentToEquityConsideration
0
CY2021Q3 us-gaap Disposal Group Including Discontinued Operation Prepaid And Other Assets Current
DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent
1117000
CY2021Q3 us-gaap Disposal Group Including Discontinued Operation Property Plant And Equipment Noncurrent
DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent
2398000
CY2021Q3 us-gaap Disposal Group Including Discontinued Operation Other Noncurrent Assets
DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets
125000
CY2021Q3 us-gaap Assets Of Disposal Group Including Discontinued Operation
AssetsOfDisposalGroupIncludingDiscontinuedOperation
3640000

Files In Submission

Name View Source Status
0000950170-21-004376-index-headers.html Edgar Link pending
0000950170-21-004376-index.html Edgar Link pending
0000950170-21-004376.txt Edgar Link pending
0000950170-21-004376-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
fmtx-20210930.htm Edgar Link pending
fmtx-20210930.xsd Edgar Link pending
fmtx-20210930_cal.xml Edgar Link unprocessable
fmtx-20210930_def.xml Edgar Link unprocessable
fmtx-20210930_htm.xml Edgar Link completed
fmtx-20210930_lab.xml Edgar Link unprocessable
fmtx-20210930_pre.xml Edgar Link unprocessable
fmtx-ex31_1.htm Edgar Link pending
fmtx-ex31_2.htm Edgar Link pending
fmtx-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending